We investigated the effect of 4-aminopyridine (4-AP) on experimental autoimmune neuritis (EAN) using a 4-AP treated group in which 4-AP was administered in the diet, and a control group (n = 10 per group). Electrophysiological and pathological assessment was performed in the sciatic nerve. The EAN clinical scores were significantly lower in the 4-AP-treated group than in the control group (p < 0.05):The motor conductance velocity two weeks post-immunization was significantly higher in the 4-AP-treated group (p < 0.05). Finally, 4-AP did not lead to pathological changes. Thus, 4-AP might be a potential therapeutic agent in demyelinating neuropathy. (C) 2017 Elsevier B.V. All rights reserved.